key: cord-1000933-a2xg7v07 authors: Qassim, S. H.; Chemaitelly, H.; Ayoub, H.; AlMukdad, S.; Tang, P.; Hasan, M. R.; YASSINE, H. M.; Al-Khatib, H. A.; Smatti, M. K.; Abdul Rahim, H. F.; Nasrallah, G.; Al-Kuwari, M. G.; Al Khal, A.; Coyle, P.; Kaleeckal, A. H.; Shaik, R. M.; Latif, A. N.; Al-Kuwari, E.; Jeremijenko, A.; Butt, A. A.; Bertollini, R.; Al Romaihi, H. E.; Al-Thani, M. H.; Abu-Raddad, L. J. title: Effects of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 Omicron infections date: 2022-03-04 journal: nan DOI: 10.1101/2022.03.02.22271771 sha: 7760df610b71feaf09455587d6feb1193d84e0dd doc_id: 1000933 cord_uid: a2xg7v07 BACKGROUND: Qatar experienced a large SARS-CoV-2 Omicron (B.1.1.529) wave that started on December 19, 2021 and peaked in mid-January, 2022. We investigated effects of Omicron subvariant (BA.1 and BA.2), previous vaccination, and prior infection on infectiousness of Omicron infections, between December 23, 2021 and February 20, 2022. METHODS: Univariable and multivariable regression analyses were conducted to estimate the association between the RT-qPCR cycle threshold (Ct) value of PCR tests (a proxy for SARS-CoV-2 infectiousness) and each of the Omicron subvariants, mRNA vaccination, prior infection, reason for RT-qPCR testing, calendar week of RT-qPCR testing (to account for phases of the rapidly evolving Omicron wave), and demographic factors. RESULTS: Compared to BA.1, BA.2 was associated with 3.53 fewer cycles (95% CI: 3.46-3.60), signifying higher infectiousness. Ct value decreased with time since second and third vaccinations. Ct values were highest for those who received their boosters in the month preceding the RT-qPCR test - 0.86 cycles (95% CI: 0.72-1.00) higher than for unvaccinated persons. Ct value was 1.30 (95% CI: 1.20-1.39) cycles higher for those with a prior infection compared to those without prior infection, signifying lower infectiousness. Ct value declined gradually with age. Ct value was lowest for those who were tested because of symptoms and was highest for those who were tested for travel-related purposes. Ct value was lowest during the exponential-growth phase of the Omicron wave and was highest after the wave peaked and was declining. CONCLUSIONS: The BA.2 subvariant appears substantially more infectious than the BA.1 subvariant. This may reflect higher viral load and/or longer duration of infection, thereby explaining the rapid expansion of this subvariant in Qatar. Qatar experienced a large severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) 1 The RT-qPCR cycle threshold (Ct) value is a measure of the inverse of viral load and correlates strongly with culturable virus; 6 thus, it can be used as a proxy for SARS-CoV-2 infectiousness. [6] [7] [8] [9] [10] [11] We investigated several effects on the RT-qPCR Ct value of Omicron variant infections in the resident population of Qatar using a cross-sectional study design. These included: subvariant (BA.1 versus BA.2), mRNA (BNT162b2 12 and mRNA-1273 13 ) vaccination status, prior infection status, reason for RT-qPCR testing, study-period week of the RT-qPCR test (to account for the evolving phase of the rapid Omicron wave), and demographic factors including sex, age, and nationality. The study population included all individuals with an RT-qPCR-confirmed SARS-CoV-2 infection in Qatar between December 23, 2021 and February 20, 2022. Coronavirus disease 2019 (COVID-19) laboratory testing, vaccination, clinical infection, and demographic data for this population were extracted from the national, federated SARS-CoV-2 databases, which include all RT-qPCR testing, reason for RT-qPCR testing, COVID-19 vaccinations, and related demographic details since the start of the pandemic. Further description of Qatar's national COVID-19 databases can be found in previous publications. 11, [14] [15] [16] [17] Every SARS-CoV-2 RT-qPCR test conducted in Qatar is classified based on the reason for testing (clinical symptoms, contact tracing, surveys or random testing campaigns, individual requests, routine healthcare testing, pre-travel, at port of entry, or other). RT-qPCR testing is performed at a mass scale. 15 About 75% of those diagnosed over recent months were diagnosed not because of appearance of symptoms, but because of routine testing. 15 Qatar has unusually young, diverse demographics, in that only 9% of its residents are ≥50 years of age, and 89% are expatriates from over 150 countries. 14, 18 Nearly all individuals were vaccinated in Qatar, however, vaccinations performed elsewhere were still recorded in the health system at the port of entry upon arrival to Qatar per country requirements. Informed by the viral genome sequencing and the RT-qPCR genotyping (Section S1), a SARS-CoV-2 infection with the BA.1 subvariant was proxied as an S-gene "target failure" (SGTF) case using the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, USA 19 ) that tests for the S- For each individual, we selected only the first positive RT-qPCR-confirmed swab during the study period. We subsequently derived a summary measure for our primary outcome, the RT-All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 4, 2022. ; https://doi.org/10.1101/2022.03.02.22271771 doi: medRxiv preprint qPCR Ct value, by averaging the Ct values of the N, ORF1ab, and S (if not an S-gene "target failure" case) genes. This average Ct value was used as the dependent variable in all analyses. Both vaccination status and prior infection status were ascertained at the time of the RT-qPCR test. Vaccination status was defined factoring the number of administered vaccine doses and months elapsed since the last vaccine dose, with one month defined as 30 days. Only vaccination with BNT162b2 12 and mRNA-1273 13 vaccines were considered in the analyses, as these have been the vaccines of choice in the COVID-19 immunization program in Qatar. 21-23 Rare occurrences of mixed vaccination regimens were excluded. Prior infection was defined as an RT-qPCR-positive test that occurred ≥90 days before the study RT-qPCR-positive test. 3, 17, [24] [25] [26] [27] [28] [29] [30] [31] An RT-qPCR-positive test that occurred <90 days prior to the study RT-qPCR-positive test was still factored in the analysis, but was not considered a prior infection. This is because this RT-qPCRpositive test and the study RT-qPCR-positive test may both reflect the same prolonged infection. [32] [33] [34] A small number of RT-qPCR tests had no recorded Ct value and were thus excluded from the analysis, but these constituted only 0.1% of all RT-qPCR tests. Otherwise, data on the remaining study variables were complete. Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards approved this retrospective study with waiver of informed consent. The study was reported following STROBE guidelines. The STROBE checklist is found in Table S1 . Frequency distributions and measures of central tendency were used to describe the study population with respect to a priori determined factors. These included Omicron infection subvariant, vaccination status (factoring dose number and months since vaccination), prior infection status, reason for RT-qPCR testing, study-period week of the RT-qPCR test, and demographic factors, namely sex, age, and nationality. Differences between BA.1 and BA.2 infections were estimated using standardized mean differences (SMDs). Association of each of these factors with Ct value was assessed using univariable linear regression analyses. Unadjusted β coefficients, 95% confidence intervals (CIs), and the F-test of overall covariate significance were reported. Adjusted β coefficients and associated 95% CIs and p-values were estimated using multivariable linear regression analyses that included all covariates in the model. The 95% CIs were not adjusted for multiplicity. Two-sided p-value <0.05 indicated statistical significance. Interactions were not considered. Statistical analyses were conducted in STATA/SE version 16. 35 Results Figure 2 shows the process of selecting the study population and Table 1 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Ct value declined gradually with age (Table 2) , perhaps reflecting slower virus clearance with aging. There were differences in Ct value by sex and nationality, but these may reflect different test-seeking behaviors for different socio-economic groups in Qatar's diverse population, or differences in the rates of prior undocumented infection by nationality. 14,36-39 Ct value was lowest for those who were tested because of symptoms and was highest for those who were tested for travel-related purposes. Ct value was lowest during the exponential-growth phase of the Omicron wave, as a large proportion of infections were recent, and was highest after the wave peaked and was declining, as a small proportion of infections were recent. Stratified analyses for each of BA.1 (Table 3 ) and BA.2 (Table 4) showed similar findings. The BA.2 subvariant appears substantially more infectious than the BA.1 subvariant, consistent with recent findings of a household study from Denmark. 40 This may reflect higher viral load and/or longer duration of infection, thereby explaining the rapid expansion of this subvariant in Qatar ( Figure 1 ). Natural immunity from previous infection and strength of vaccine immunity correlate with less infectious breakthrough infections, as observed for earlier SARS-CoV-2 variants. 11 Symptomatic infection and older age are associated with higher infectiousness. A small number of RT-qPCR tests had no available Ct value and were thus excluded from the analysis, but these constituted only 0.1% of all RT-qPCR tests. The study was implemented on documented RT-qPCR-confirmed infections, but other infections may have occurred but were All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 4, 2022. ; https://doi.org/10.1101/2022.03.02.22271771 doi: medRxiv preprint never documented. It is possible that infections in those with prior infection or those vaccinated are less likely to be diagnosed, perhaps because of minimal or no symptoms. Nevertheless, RT-qPCR testing in Qatar is done at a mass scale, where a significant proportion of the population is being tested every week. 15 The majority of infections are identified not because of symptoms, but because of routine testing for other reasons (Table 1) . 15 The date of symptom onset was not available for symptomatic cases. Therefore, an analysis factoring the duration between symptom onset and RT-qPCR test was not possible. The study population consists of mostly working-age adults and thus the results may not necessarily be generalizable to other population groups, such as the elderly. The analyses controlled for sex, age, and nationality but it was not possible to control for other factors, such as comorbidities or socio-economic factors, as data on these factors were not available. Of note that the number of individuals with severe chronic conditions is small in Qatar's young population. 14, 41 The national list of vaccine prioritization included only 19,800 individuals of all age groups with serious co-morbid conditions to be prioritized in the first phase of vaccine rollout. 15 Factoring nationality in the analyses may have (partially) controlled socio-economic differences/occupational risk, in consideration of the association between nationality and occupation in Qatar. 14, [36] [37] [38] [39] BA.1 and BA.2 ascertainment was based on proxy criteria; presence or absence of SGTF using the TaqPath Kit, but this method of ascertainment is well established not only for Omicron subvariants, but also for other variants such as Alpha. 20,30,42 Some Omicron infections may have been misclassified Delta infections, but this is not likely, as Delta incidence was limited during the study (Section S1). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Time since vaccination was associated with lower Ct value, mirroring the established pattern of waning vaccine effectiveness. 4 Unexpectedly, however, the Ct value for those who had their second dose >6 months earlier was lower than that among unvaccinated persons. With the high vaccine coverage in Qatar (exceeding 85%), the unvaccinated group may be different in other uncontrolled attributes from the vaccinated group. For example, those unvaccinated may have chosen not to receive the vaccine because of undocumented prior infection and thus are not truly immune naïve. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article. SHQ co-designed the study, performed the statistical analyses, and co-wrote the first draft of the article. HC co-designed the study, supported the statistical analyses, and co-wrote the first draft of the article. LJA conceived and co-designed the study, led the statistical analyses, and co-wrote the first draft of the article. PT and MRH conducted the multiplex, RT-qPCR variant screening and viral genome sequencing. HY, HAK, and MS conducted viral genome sequencing. All authors contributed to data collection and acquisition, database development, discussion and interpretation of the results, and to the writing of the manuscript. All authors have read and approved the final manuscript. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Dr. Butt has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. Otherwise we declare no competing interests. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ 2021;372:n579. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Abbreviations: IQR, interquartile range; RT-qPCR, real-time reverse-transcription polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SMD, standardized mean difference. * SMD is the difference in the mean of a covariate between groups divided by the pooled standard deviation. An SMD <0.1 indicates minimal differences between groups. † Nationalities were chosen to represent the most populous groups in Qatar. ‡ These comprise 44 other nationalities in Qatar. § An RT-qPCR-positive test that occurred <90 days before the study RT-qPCR-positive test was included separately in the analysis, but was not considered a prior infection. This RT-qPCR-positive test and the study RT-qPCR-positive test may both reflect the same prolonged infection. ¶ Prior infection was defined as an RT-qPCR-positive test that occurred ≥90 days before the RT-qPCR-positive test that is included in the study. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The two-tailed F-test of the univariable analysis. † RT-qPCR Ct value was adjusted for age-group, sex, nationality, Omicron subvariant, reason for RT-qPCR test, RT-qPCR test study-period week, vaccination status, and prior SARS-CoV-2 infection. ‡ The 10-19 age group was chosen as a reference, and not the <10-age group, because of the different manifestations of this infection in small children. § Nationalities were chosen to represent the most populous groups on Qatar. ¶ These comprise 44 other nationalities in Qatar. ** An RT-qPCR-positive test that occurred <90 days before the study RT-qPCR-positive test was included separately in the analysis, but was not considered a prior infection. This RT-qPCR-positive test and the study RT-qPCRpositive test may both reflect the same prolonged infection. † † Prior infection was defined as an RT-qPCR-positive test that occurred ≥90 days before the RT-qPCR-positive test that is included in the study. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. where Delta incidence was limited. Accordingly, any PCR-positive test during the study duration, between December 23, 2021 and February 20, 2022, was assumed to be an Omicron infection. Of note that the study duration started on December 23, 2021, and not on December All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Table 1 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Qatar viral genome sequencing data. Data on randomly collected samples Protection against the Omicron Variant from Previous SARS-CoV-2 Infection Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19 Association between SARS-CoV-2 Viral Load, and Age in Households SARS-CoV-2 infectivity by viral load, S gene variants and demographic factors and the utility of lateral flow devices to prevent transmission Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Characterizing the Qatar advancedphase SARS-CoV-2 epidemic Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 34 mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity National Study Group for Covid Epidemiology. Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study Estimating protection afforded by prior infection in preventing reinfection: Applying the test-negative study design Year-long COVID-19 infection reveals withinhost evolution of SARS-CoV-2 in a patient with B cell depletion Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months Multiplexed RT-qPCR to screen for SARS-COV-2 B.1.1.7, B.1.351, and P.1 variants of concern V.3. dx National Study Group for C-V. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar Qatar viral genome sequencing data. Data on randomly collected samples One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar COVID-19 (SARS-CoV-2) outbreak monitoring using wastewater-based epidemiology in Qatar World Health Organization. Tracking SARS-CoV-2 variants Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage Protection against the Omicron Variant from Previous SARS-CoV-2 Infection Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar TaqPath™ COVID-19 CE-IVD RT-PCR Kit instructions for use SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 34 We acknowledge the many dedicated individuals at Hamad Medical Corporation, the Ministry of Public Health, the Primary Health Care Corporation, the Qatar Biobank, Sidra Medicine, and Weill Cornell Medicine -Qatar for their diligent efforts and contributions to make this study possible.The authors are grateful for support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, as Acknowledgements Abbreviations: NA: not applicable.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 4, 2022. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.